The U.S. Food and Drug Administration is moving to fast-track reviews of two experimental Merck drugs with ...

Merck says Keytruda plus Padcev improved survival and response rates versus chemotherapy in a Phase 3 muscle-invasive bladder ...

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

While one of the drugs reportedly slated for fast-track review is the cholesterol pill Enlicitide Decanoate, the other is ...

Merck, Pfizer and Astellas, which in August reported similar results from a Phase 3 study of the combination in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based ...

In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

Merck & Co has a lower P/E than the aggregate P/E of 57.45 of the Pharmaceuticals industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that ...

Patients with polycythemia vera (PV), a rare cancer characterized by overabundant red blood cells, have endured years of middling progress in their therapeutic options. | Patients with polycythemia ...

CA1, Zoetis’ Dectomax-CA1 receive conditional FDA approval to treat and prevent New World screwworm in beef cattle.

It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry.